Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 11, 2011 - Issue 11
Submit an article Journal homepage
38
Views
8
CrossRef citations to date
0
Altmetric
Special Report

Role of sorafenib in renal cell carcinoma: focus on elderly patients

Giuseppe Procopio Fondazione Istituto Nazionale Tumori, Via G Venezian 1, 20133 Milan, Italy. [email protected]
Pages 1689-1692 | Published online: 10 Jan 2014

References

  • Bellmunt J, Eisen T, Szczylik C, Mulders P, Porta C. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU Int. DOI: 10.1111/j.1464–410X.2010.09829.x (2010) (Epub ahead of print).
  • Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P. Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat. Rev.36, 16–23 (2010).
  • Zustovich F, Lombardi G, Pastorelli D et al. Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. OA J. Urol.3, 1–14 (2011).
  • Escudier B, Eisen T, Stadler WM et al.; TARGET study group. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356, 125–134 (2007).
  • Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol.27, 3312–3318 (2009).
  • Rini BI, Szczylik C, Tannir NM et al. AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, Phase II study. J. Clin. Oncol.29(Suppl. 7), (2011) (Abstract 309).
  • Procopio G, Verzoni E, Bracarda S et al. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br. J. Cancer104, 1256–1261 (2011).
  • Stadler WM, Figlin RA, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer116, 1272–1280 (2010).
  • Pascual D, Borque A. Epidemiology of kidney cancer. Adv. Urol.2008, 782381 (2008).
  • Bellmunt J, Calvo E, Castellano D et al. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemother. Pharmacol.63(Suppl. 1), S1–S13 (2009).
  • Eisen T, Oudard S, Szczylik C et al.; TARGET study group. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J. Natl Cancer. Inst.100, 1454–1463 (2008).
  • Bukowski RM, Stadler WM, McDermott DF et al. Safety and efficacy of sorafenib in elderly patients treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program. Oncology78, 340–347 (2010).
  • Beck J, Procopio G, Bajetta E et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann. Oncol.22, 1812–1823 (2011).
  • Bukowski RM. Safety and efficacy of sorafenib in elderly patients (pts) >65 years: a subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. J. Clin. Oncol.26 (2008) (Abstract 5045).
  • Townsley CA, Pond GR, Oza AM et al. Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Clin. Cancer Res.12(7 Pt 1), 2141–2149 (2006).
  • Procopio G, Bellmunt J, Dutcher JP et al. Sorafenib in older patients with advanced renal cell carcinoma: subanalysis by age of an integrated database of 8 company-sponsored clinical trials. Ann. Oncol.21(Suppl. 8), (2010) (Poster 906P).
  • Fratino L, Bearz A, Polesel J, Lestuzzi C, Vaccher E, Tirelli U. Use of a comprehensive geriatric assessment (CGA) to guide the use of sorafenib in unfit elderly patients (EP) with metastatic renal cell carcinoma (RCC). J. Clin. Oncol.28(Suppl.), (2010) (Abstract e19636).
  • Hutson TE, Bukowski RM, Rini BI et al. A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol.29(Suppl.), (2011) (Abstract 4604).
  • Bajetta E, Ravaud A, Bracarda S et al. A randomized Phase III study of firstline bevacizumab (BEV) plus interferonα 2a (IFN) versus IFN alone in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol.26(Suppl.), (2008) (Abstract 5095).
  • Hutson TE, Calvo E, Escudier BJ et al. Everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the RECORD-1 study. Presented at: ASCO 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA, 5–7 March 2010 (Abstract 362).
  • Hudes G, Carducci M, Tomczak P et al.; Global ARCC Trial. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356, 2271–2281 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.